Biomarkers, CDx & Precision Medicine 2026
.png)
Congress Centre Basel, Switzerland
.png?width=685&height=180&name=BIOMCDxPREMED%20LOGO%20(Light%20Contrast).png "BIOMCDxPREMED LOGO (Light Contrast)")
Programme
Day
AI-Powered Precision Medicine
Panel Discussion• AI tools for treatment customisation and enhancement of patient care
• How to ensure the successful incorporation of AI into precision medicine
• AI as a tool for data analysis & integration
Translational Biomarkers For Evaluating Biologic Drug Efficacy
Industry PresentationThis presentation explores how translational biomarkers support the development and evaluation of biologic drugs by linking molecular mechanisms to clinical outcomes. It highlights their role in measuring efficacy, guiding patient selection, and improving decision making across preclinical and clinical studies, ultimately enabling more precise and effective therapeutic strategies.
From Silos to Alliances – Rethinking Collaboration in Precision Medicine
Panel DiscussionDigital Biomarkers, Cancer Networks, and Clinical Action
Industry PresentationAdvancement of digital diagnostics and clinical utility
Bringing cancer testing from global to local through enhanced networks
Algorithms to enhance patient identification globally
Biomarkers, Omics & AI for Early Diagnostics
Roundtable DiscussionIVDR Regulations & Their Impact
Panel Discussion• Overview of IVDR Compliance requirements
• Impact on Companion Diagnostics Development
• Challenges & Opportunities for Industry Stakeholders
Icon Presentation
Solution Provider PresentationLiquid Biopsy Approaches Using Urinary Biomarkers in CKD Drug Development
Industry Presentation• Urinary biomarker liquid biopsies, including exosomal miRNA profiling, provide a scalable, noninvasive way to monitor CKD disease activity and treatment effects.
• Distinct urinary miRNA signatures differentiate pharmacodynamic drug effects from CKD progression and reveal treatment-modulated renal compartments, aiding precision development strategies.
Biomarker Strategies In Neurodegenerative Therapeutics
Panel Discussion• Multimodal biomarker strategies – fluid, imaging and digital measures
• Incorporating biomarkers into neurodegenerative drug development and trials
• Advancing biomarkers from discovery to clinical utility and regulatory acceptance
Quanterix Presentation
Solution Provider PresentationAdvance Precision Medicine In Chronic Disease Through Early Detection & Digital Diagnostics
Industry PresentationDrive early detection and diagnosis
AI-enabled diagnostics for precision treatment
GD2 as biomarker candidate for GD2-ADC development: Strategy and Evidence for Complex Biomarker Assay Validation
Industry PresentationGD2 is a glycosphingolipid sparsely expressed in normal tissues but overexpressed in a number of cancers, validated clinically in pediatric neuroblastoma. GD2 promotes malignant traits and is found in membranes and circulation. Strategy and challenges for validating GD2 biomarker assays are outlined.
Hologic Diagenode Presentation
Solution Provider PresentationDesigning Biomarker Trials
Industry PresentationQuantum Computing For Biomarker Discovery
Roundtable DiscussionExploring the Clinical Application of Single Cell Analysis
Industry Presentationo Liquid biopsy and circulating tumor cells
o Molecular analysis of rare single cells and its clinical applications
o Liquid biopsy beyond blood
New Frontiers In Precision Medicine – The Neurology Example
KeynoteMission Bio Presentation
Solution Provider PresentationAlmac Presentation
Solution Provider PresentationPrecision Medicine: Drug/CDx Regulatory Strategy in the US and EU
Industry PresentationCompanion diagnostics guide optimal patient treatment, but their development poses multiple challenges and requires efficient coordination between drug developers, IVD companies, and Health Authorities. This presentation shares a Pharma company’s perspective on regulatory strategies enabling successful drug/CDx co-development and co-approval in the US and EU.
Seer Presentation
Solution Provider PresentationBD Presentation
Solution Provider PresentationDiagnexia Analytics Presentation
Solution Provider PresentationBiomarker Modalities In Early Development Of Molecular Glue Degraders For Oncology And Immune-Mediated Diseases
Industry PresentationTargeted Protein Degradation with Molecular Glue is a new strategy for small-molecule drugs to target undruggable proteins.
Molecular Glue Degraders represent novel approach to treat various autoimmune, inflammatory, oncological and neurological diseases. Biomarker development and deployment to monitor direct target degradation, downstream pharmacodynamic changes and treatment responses will be discussed.
Single Molecule And Single Cell Analysis Of Biomarkers In Precision Medicine And Drug Development
Industry Presentation• Single molecule techniques are not only ultrasensitive but enable absolute quantification, precision and accuracy as well as being high throughput
• Organoid and human primary tissue analysis demonstrates patient-specific and drug-specific responses
• Single cell analysis of human primary material demonstrates heterogeneity in responses
Luminex Presentation
Solution Provider PresentationFrom Sequencing to Clinical Decision: Integrating NGS into Standardized Companion Diagnostic Workflows — A Roadmap from RUO to Clinical Implementation
Industry PresentationNext-Generation Sequencing (NGS) is transforming companion diagnostics but remains largely in the Research Use Only space. This talk outlines the roadmap toward clinical implementation, focusing on workflow standardization, assay reproducibility, bioinformatics harmonization, and regulatory readiness required to integrate NGS into routine diagnostic laboratory workflows.
Enumeration And Characterisation Of Circulating Tumour Cells Using Imaging Flow Cytometry And Artificial Intelligence (AI)
Industry PresentationCompanion Diagnostic Development Strategies
Industry PresentationLiquid Biopsy in Cancer Pathways - Welsh Perspective
Industry Presentation• Real world implementation of ctDNA testing into the lung cancer diagnostic pathway across NHS Wales
• Current role of liquid biopsy in routine cancer care in lung and breast cancer
• Opportunities, challenges and future directions for precision oncology across multiple tumour types through the QuicDNA Max study
Optimising Liquid Biopsy, MCED and MRD for Clinical Decision-Making
Panel DiscussionRules Based Medicine Presentation
Solution Provider PresentationSynexa Presentation
Solution Provider PresentationApplication and Integration Of Proteomic Biomarkers In Precision Medicine
Panel Discussion• Biomarker discovery,
• Diagnostics & prognostics,
• Patient stratification & precision medicine
Illumina Presentation
Solution Provider PresentationOlink Presentation
Solution Provider PresentationMedInsights Presentation
Solution Provider PresentationAccelerating CDx Integration in Drug Clinical Trials: What It Takes to Succeed Under IVDR
Solution Provider PresentationManaging interventional Clinical Performance Studies (CPS) under the IVDR remains one of the most challenging elements of drug–diagnostic co development. The highly decentralized requirements across National Competent Authorities and ethics committees introduce significant variability and potential delays, underscoring the need for seamless coordination between pharmaceutical and diagnostic partners. This session will examine the key challenges associated with Annex XIV CPS submissions and present practical strategies to streamline planning, align regulatory activities with drug development timelines, and enhance collaboration with critical European regulatory stakeholders.
Preclinical Strategies To Define Biomarkers For Clinical Translation
Industry PresentationClinical Single-Cell Sequencing to Uncover Determinants of Response and Guide Treatment Selection
Industry PresentationCancer treatment efficacy depends on tumor, immune, and stromal features that are not currently accessible in clinical practice. One Biosciences developed OneMap™, combining single-nucleus profiling and AI to identify cellular and molecular determinants of response. We will present recent studies uncovering single-cell biomarkers for immune checkpoint inhibitors, antibody-drug conjugates, and bispecific antibodies, and demonstrating prospective clinical applications.
Flow Cytometry In Patient Monitoring
Industry PresentationTranslating Biomarkers from Discovery to Clinical Use
Panel Discussion• Using biomarkers for patient selection
• Choosing and validating biomarker endpoints
• Lessons learnt in oncology for other therapeutics
Precision Medicine In Neuroscience: The Role Of Digital Biomarkers
Industry PresentationArcoris Bio Presentation
Solution Provider PresentationA Regulatory Perspective on the Expanding Reach of Personalized Medicine
Industry Presentation• Companion diagnostics (CDx) have primarily advanced precision medicine in oncology, driven by research and enhanced understanding of cancer-related genetic pathways.
• CDx holds promise to improve therapeutic success rates in other areas such as immunology, neurological diseases, and rare/orphan conditions.
• Regulatory hurdles challenge the broader adoption of CDx, highlighting a need to evolve current regulatory paradigms for expansion beyond oncology
Digital Health Technology Adoption in Clinical Development
Industry PresentationThis presentation explores digital health technologies transforming clinical development by fostering deeper alignment between technology providers and pharma. Amid regulatory hurdles, technical challenges and an increasingly complex, evolving landscape, it highlights the efforts needed to build a coherent, collaborative ecosystems that accelerate innovation and unlock new patient‑centric possibilities.
The Molecular Evolution of Glial Brain Tumors
Industry Presentation1. Gliomas evolve by increasing programs involved in cell cycling, cellular differentiation and remodeling of the extracellular matrix
2. IDHmutant oligodendrogliomas evolve on the same epigenetic axis as IDHmutant astrocytomas
3. The methylome remains stable during IDHwt glioblastoma progression
FORX-428: Exploiting PARG Inhibition To Target Replication Stress In Cancer Cells
Industry Presentationo PARG inhibition as a novel strategy to exploit replication stress vulnerabilities in cancer, expanding the therapeutic landscape beyond classical HRD-associated tumors.
o Preclinical and translational evidence supporting biomarkers of response, including replication stress and DNA damage response alterations, to enable patient stratification.
o Clinical development of FORX-428: integrating molecular profiling, ctDNA monitoring, and translational biomarkers to guide precision medicine approaches.
Labcorp Presentation
Solution Provider PresentationCellCarta Presentation
Solution Provider PresentationMethylomics Presentation
Solution Provider PresentationMetabolomics In Biomarker Analysis
Industry PresentationClinical Trial Outcome Prediction Through Systematic Data Enrichment: Integrating Pharmacokinetic and Biomarker Data
Industry PresentationClinical trial success prediction models plateau at ROC-AUC 0.65 despite increasing algorithmic complexity. We hypothesize limitations stem from data quality rather than model architecture. Auditing public datasets reveals major quality issues. Integrating underexploited biological variables (pharmacokinetics, biomarkers) and rigorous data curation may unlock predictive gains more effectively than complex algorithms.
Translating Biomarkers from Bench to Bedside
Industry PresentationUntargeted Biomarker Discovery for Toxicological & Pharmacological Investigations in Pre-Clinical Drug Discovery Programs by Spatial Tissue Mass Spectroscopy Imaging Platform
Industry Presentation• Background on Tissue Based Mass Spectrometry: Principles & Applications
• Tissue Based Multi-Omics applications in drug discovery
• Untargeted Biomarker Discovery
• Drug Safety Prediction
Using Biomarkers To Drive Decision-Making In Neurodegenerative Diseases
Industry PresentationEarly signals to progress a compound further in development or to stop the program is essential to ensure that resources are utilized judiciously whether in a biotech or pharma setting. Biomarkers if available can provide the guidance for the go-no-go decisions.
Liquid Biopsy Biomarkers For Disease Monitoring
Industry PresentationMetabolon Presentation
Solution Provider PresentationFoundation Medicine Presentation
Solution Provider PresentationAI-Powered Biomarkers And The Next Wave Of Innovation In Precision Oncology
Industry Presentation• The increasing complexity of clinical biomarkers development
• The opportunity offered by AI-powered biomarkers and multimodal data
• The playbook that oncology translational organizations can follow
Start Up Zone Presentation: Cyentia Biosource
Industry PresentationCerba Research Presentation
Industry PresentationBuilding Integrated Precision Diagnostics of the Future – Uniting Biomarkers, CDx, Spatial Biology & AI
Panel DiscussionCreating a unified precision medicine ecosystem that improves patient stratification and treatment selection
How spatial biology and multimodal datasets are reshaping our understanding of disease mechanisms, tumor heterogeneity, and therapeutic response
Key challenges to scaling next-generation precision diagnostics
Start Up Zone Presentation: Avenna
Industry PresentationAI-Enabled Clinical Trial Innovation - From Biomarker Data to Decision
Panel DiscussionHow AI is accelerating clinical trial design and execution by transforming biomarker data into faster, more informed decision-making
The role of predictive analytics and real-world data in improving patient selection, trial efficiency, and probability of clinical success
Balancing innovation with trust: ensuring transparency, regulatory compliance, data quality, and human oversight in AI-enabled trials
BioAgilytix Presentation
Solution Provider PresentationFrom Data To Design: AI-Driven Generative Biology And The Future Of Personalized Medicine
Keynote"From Data to Design" describes a shift from using AI to analyze biomedical data toward using AI to design biological interventions and accelerate discovery. This transition is enabled by the convergence of large-scale biomedical data, foundation models, and a new generation of AI-native laboratories that integrate automation, robotics, and AI agents into experimental workflows.
Regulatory Considerations for the Emerging Era of Computational Precision Biomarkers
Industry PresentationBuilding computational biomarkers early into the precision medicine development process can unlock significant therapeutic value previously restricted by human limitations in pathological evaluations. Learn about the regulatory considerations that can facilitate the successful development of computational biomarkers from research tools into clinical solutions.
Pharmacological Audit Trail (PhAT)
Industry PresentationStart Up Zone Presentation: UltraBright Biotech
Industry PresentationStart Up Zone Presentation: Histomography
Industry PresentationAI Supported Histopathology - Implementation & Validation
Industry PresentationDespite rapid algorithmic progress in histopathology AI over the past eight years, clinical adoption remains limited — even where performance benefits are well-documented. What stops AI models from making the leap from publication to practice? This talk addresses the practical realities of deploying AI in a clinical pathology setting: from technical integration and workflow adaptation to prospective validation and regulatory considerations. Drawing on real-world experience, we discuss key challenges, lessons learned, and the path toward trustworthy, clinically impactful AI
Start Up Zone Presentation: Ingenix
Industry PresentationOvercoming Challenges in Deploying Foundation Models, LLMs and Agentic AI for Pathology Workflows
Panel DiscussionTissue-Based Imaging And Analytical Workflows: Unlocking Insights Into Target Biology
Industry PresentationTissue-based imaging, combined with iterative analytical workflows, is transforming our ability to interrogate target biology in situ. This talk will highlight the integration of multiplex imaging and image analysis pipelines to identify pharmacodynamic and efficacy biomarkers, emphasizing the role of iterative refinement in improving robustness, reproducibility, and biological insight.
OracleBio Presentation
Solution Provider PresentationArtificial Intelligence for Non-Clinical Safety: Past, Present and the Long Road Ahead
Industry Presentation- Foundation models have enabled harnessing data at scale without the annotation bottleneck: can this break down the siloes of the drug development process
- What might the scalability question look like? Thinking about scaling laws from a pharma perspective
- What might be the implications for business models in pharma – will decades of historical data be the eventual moat for big pharma?
Artificial Intelligence In Pathology and Biomarker Testing
Roundtable DiscussionHarnessing Digital Pathology& AI To Enhance Understanding Of The TME
Industry PresentationLabcorp Presentation
Solution Provider PresentationFrom Digital Pathology To Precision Medicine: Scaling AI-Driven Image Analysis
Industry PresentationThe transformation of digital pathology and safety assessment increasingly depends on the ability to connect data, platforms, and analytical approaches across globally distributed laboratories, enabling scalable AI applications. At AstraZeneca, we are building an integrated ecosystem that connects scanners, viewing platforms, and analysis environments within the pathology workflow to support next-generation safety prediction and precision medicine programs. In parallel, we are exploring the harmonization of historical data to develop proprietary foundation AI models, with the goal of scaling AI-guided safety predictions and reshaping the future digital pathology landscape.
Patholytix Presentation
Solution Provider PresentationProscia Presentation
Solution Provider PresentationThe Evolving Role of Pathology In Precision Oncology
Industry PresentationAI In The Daily Workflow Of Pathology: From Image Analysis To Voice and Data-Driven Decision Support
Industry PresentationTo Multiplex Or Not To Multiplex- The Question In Preclinical Drug Development
Industry PresentationOverview of histology and biomarker support in preclinical drug discovery, including applications of classical multiplex immunofluorescence (mIF)
Introduction to pseudo-IF image processing and advanced image analysis workflows to address key project questions
Comparative perspective on mIF, pseudo-IF, and emerging approaches (e.g., virtual staining) to guide technology selection in preclinical research
Indica Labs Presentation
Solution Provider PresentationStain Transfer for Pathology: Learning Cross Stain Representations from H&E
Industry PresentationThis work focuses on stain transfer, learning mappings from H&E to PAS or Fluoro-Jade using weakly supervised learning based on paired images only. Results show biologically meaningful signal but also intrinsic limits driven by data ambiguity. Performance is data-limited rather than method-limited, making investment in diverse paired stains the key lever for progress.
Deploying Computational Pathology Across the Pharma Pipeline
Panel DiscussionDigital Image Analysis & AI For Drug Discovery
Industry PresentationComputational Pathology Diagnostic Solution Hackathon - Presentations, Judging, & Winning Team Announcement
Industry PresentationThe Computational Pathology Diagnostic Solution Hackathon will bring together clinicians, pathologists, AI experts, pharma biomarker teams, diagnostics partners, and regulatory stakeholders to develop practical computational pathology diagnostic solutions for real-world biomarker and clinical decision-making challenges.
The session will focus on four key questions:
1. What unmet patient or diagnostic need are we solving?
2. Is the right data available to build the model?
3. How could the model support biomarker or diagnostic development?
4. What regulatory, workflow, and deployment factors must be
considered?
Computational Pathology Diagnostic Solution Hackathon: Presentations
Industry PresentationThe Computational Pathology Diagnostic Solution Hackathon will bring together clinicians, pathologists, AI experts, pharma biomarker teams, diagnostics partners, and regulatory stakeholders to develop practical computational pathology diagnostic solutions for real-world biomarker and clinical decision-making challenges.
The session will focus on four key questions:
1. What unmet patient or diagnostic need are we solving?
2. Is the right data available to build the model?
3. How could the model support biomarker or diagnostic
development?
4. What regulatory, workflow, and deployment factors must be
considered?
5. Clinical Validity
Predictive AI Tools for Oncology Decision Support and Clinical Outcomes
Industry PresentationAgentic AI in the Clinic: How LLM Co-Pilots Will Reshape Diagnostic Workflows
Industry PresentationLarge language models are evolving from passive assistants into agentic co-pilots that reason across imaging, pathology, genomics, and clinical text. This talk shows how LLM-based agents can structure tumor boards, match patients to trials, and orchestrate diagnostic workflows at the point of care - and what foundation models, evaluation, and regulation must deliver to make this clinically real.
The Geneva University Hospitals Framework For Clinically Validating Digital Pathology Tools
Industry PresentationThe greatest challenge in computational pathology is not building algorithms, it is validating them for deployment into clinical routine. At Geneva University Hospital, operating a fully digital primary diagnostic pipeline, we developed a practical framework for the development, validation and deployment of clinical AI tools. We share our experience and templates to help to turn algorithms into clinically used tools.
From Screening to Diagnosis: Applying AI and Digital Pathology in Women’s Health
Industry PresentationA Year Of Using AI In Routine Diagnostics – How Did It Change Us?
Industry PresentationThe TUM Institute of Pathology uses AI for prostate cancer detection since 2025 in routine diagnostics. Many things had to be prepared for that, including the setup of a digital infrastructure and proper workflow change management. But was it worth the effort? We shed light into the implications and effects of digital and AI-supported sign-out.
How Artificial Intelligence May Solve Diagnostic and Prognostic Challenges in Classic Hodgkin Lymphoma
Industry PresentationClassic Hodgkin lymphoma diagnosis and prognosis remain uncertain due to scarce Hodgkin Reed-Sternberg (HRS) tumor cells, heterogeneous tumor microenvironment (TME), and variable PET/CT interpretation. Emerging AI tools—digital pathology, radiomics, and multimodal models - may improve diagnostic accuracy, risk stratification, and TME analysis. Evidence is mostly retrospective and single-center, requiring larger validated datasets and standardized frameworks for reliable clinical implementation.
From Algorithm to Routine Practice: Building a Repeatable Implementation Pipeline for AI in Pathology
Industry Presentation
Lunch Break
Morning Break & Refreshments
Close of Day One & Networking Drinks Reception
Morning Break & Refreshments
Afternoon Break & Refreshments
Lunch Break
End of Event
Breakfast Session: Investing in Precision Medicine: The Founder & Investor Perspective
Innovation PresentationCome together over breakfast to discuss how investors and VCs are identifying, funding, and supporting breakthrough science in precision medicine, alongside a first-hand founder perspective on the journey from securing investment and scaling a company
No sessions found matching your filters.
.jpg?length=600&name=1048e2c3-e8c7-4b49-9c34-abc9914eac2c-2-11764368speaker_photo-Jutta-Eichler-(2).jpg)
.png?length=600&name=1.GenScriptCorporation_Logo_EN_Horizontal_FullColor%20(2).png){kind=logo}
.png?length=600&name=9eaa81ee-5bbe-4b99-86f7-23f16ccb27a8-2-5668375logo-PersonalisCorporateLogo-(2).png)
.jpg?length=600&name=74dfee8e-75c7-46e0-9f51-31b709af2ede-2-5668375logo-Nanion_logo_black_RGB_300dpi-(2).jpg){kind=logo}
.jpg?width=2819&height=1174&name=74dfee8e-75c7-46e0-9f51-31b709af2ede-2-5668375logo-Nanion_logo_black_RGB_300dpi-(2).jpg){kind=logo}
